

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Matsumoto N, Arase Y, Seko Y, Imai N, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Kobayashi M, Suzuki Y, Saitoh S, Suzuki F, Ikeda K, <u>Kumada H</u> , Aida K, Kobayashi T.	Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of < 126 mg/dl.	Hepatol Res	42	558-563	2012
Imai N, Ikeda K, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, <u>Kumada H</u> .	Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.	Japanese Journal of Clinic	42	175-182	2012
Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, Imai N, Kobayashi M, Sezaki H, Matsumoto N, Saitoh S, Hosaka T, Ikeda K, <u>Kumada H</u> , Ohmoto Y, Amakawa K, Hsieh SD, Ogawa K, Tanabe M, Tsuji H, Kobayashi T.	Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients.	Hepatol Res	42	264-272	2012
Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Dennis Hernandez, Fei Yu, Fiona McPhee, <u>Kumada H</u> .	Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.	J Hepatol	2012. 11.012	In press	2012
Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Wenhua Hu, Timothy Eley, Fiona McPhee, Eric Hughes, <u>Kumada H</u> .	Dual Oral Therapy with Daclatasvir and Asunaprevir for Patients with HCV Genotype 1b Infection and Limited Treatment Options.	J Hepatol	2012. 09.037	In press	2012
Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, <u>Kumada H</u> .	Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.	Hepatology	10. 1002	In press	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Suzuki F, Suzuki Y, Sezaki H, Akuta N, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Mineta R, Watahiki S, Kobayashi M, Nakayasu Y, Tsuda H, Aoki K, Yamada I, <u>Kumada H.</u>	Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients.	Hepatol Res	10.1111	In press	2012
Ikeda K, Izumi N, Tanaka E, Yotsuyanagi H, Takahashi Y, Fukushima J, Kondo F, Fukusato T, Koike K, Hayashi N, <u>Kumada H.</u>	Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis B.	Hepatol Res	1872-034	In press	2012
Tadokoro K, Kobayashi M, Suzuki F, Tanaka C, Yamaguchi T, Nagano M, <u>Kumada H.</u>	Comparative quantitative analysis of hepatitis C mutation at amino acids 70 and 91 in the core region by the Q-invader assay.	J Virol Methods	10.1016/2012.10.011	In press	2012
Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, <u>Kumada H.</u>	Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study.	J Gastroenterol	10.1007/0535-012-0688-7	In press	2012
Osaki Y, Ikeda K, Izumi N, Yamashita S, <u>Kumada H.</u> , Hatta S, Okita K.	Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers.	J Gastroenterol	10.1007/00535-012-0685-x	In press	2012
Yamada I, Suzuki F, Kamiya N, Aoki K, Sakurai Y, Kanou M, Matsui H, <u>Kumada H.</u>	Safety, pharmacokinetics, and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection.	J Viral Hepat	19	112-119	2012
Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, <u>Kumada H.</u>	Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C.	J Viral Hepat	19	134-142	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, Kobayashi M, Sezaki H, Saitoh S, Hosaka T, Ikeda K, <u>Kumada H</u> , Kobayashi T.	Effect of type 2 diabetes on risk for malignancies included hepatocellular carcinoma in chronic hepatitis C.	Hepatology	10. 1002/ 26087	In press	2012
Seko Y, Ikeda K, Kawamura Y, Fukushima T, Hara T, Sezaki H, Hosaka T, Akuta N, Suzuki F, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, <u>Kumada H</u> .	Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma.	Hepatol Res	10. 1111/ 12041	In press	2013
今井則博、池田健次、瀬古裕也、原 祐、大野敦司、松本直樹、川村祐介、保坂哲也、小林正宏、斎藤 聡、瀬崎ひとみ、芥田憲夫、鈴木文孝、鈴木義之、荒瀬康司、 <u>熊田博光</u>	ミリプラチン動注化学療法を併用したラジオ波凝固療法	肝臓	53(6)	351-354	2012
朝比奈靖浩、泉 並木、桶谷 眞、 <u>熊田博光</u> 、小池和彦、鈴木文孝、滝川 一、田中 篤、坪内博仁、林 紀夫、平松直樹、四柳 宏	C型肝炎治療ガイドライン(第1版) 日本肝臓学会肝炎診療ガイドライン作成委員会	肝臓	53(6)	355-395	2012
<u>熊田博光</u> 、岡上 武	C型代償性肝硬変を対象としたペグインターフェロンアルファ-2bとリバビリン併用投与試験	肝臓	53 (12)	803-813	2012
原 祐、芥田憲夫、福島泰斗、瀬古裕也、川村祐介、瀬崎ひとみ、保坂哲也、小林正宏、斎藤 聡、鈴木義之、鈴木文孝、荒瀬康司、池田健次、小林万利子、 <u>熊田博光</u>	高齢者C型慢性肝炎に対するテラプレビル1500mg減量投与のパイロット・スタディ	肝臓	53 (10)	624-626	2012
小関 至、狩野吉康、豊田成司、高橋祥一、川上由育、茶山一彰、芥田憲夫、鈴木文孝、 <u>熊田博光</u>	PEG-IFN/Ribavirin/Telaprevir 三剤併用療法における薬剤投与率の抗ウイルス効果におよぼす影響	肝臓	53(2)	69-77	2012
Nishimura T, Yamaguchi K, Fujii H, Okada Y, Yokomizo C, Niimi T, Sumida Y, Yasui K, Mitsuyoshi H, Minami M, Umemura A, Shima T, <u>Okanoue T</u> , Itoh Y.	Prediction of a favorable clinicalcourse in hepatitis C virus carriers with persistently normal serum alanine aminotransferase levels: A long-term follow-up study.	Hepatol Res	(in press)	(in press)	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Nishimura T, Yamaguchi K, Hashimoto H, Niimi T, Yokomizo C, Fujii H, Minami M, Sakamoto M, Ohnishi N, Nagao Y, Okita M, Umemura A, Shima T, <u>Okanoue T.</u>	Treatment extension may benefit female genotype 1 chronic hepatitis C patients with complete early virological response to peginterferon alfa-2band ribavirin combination therapy.	Hepatol Res	42	966-973	2012
Fujii H, Itoh Y, Ohnishi N, Sakamoto M, Ohkawara T, Sawa Y, Nishida K, Ohkawara Y, Yamaguchi K, Minami M, <u>Okanoue T.</u>	Factors associated with the overall survival of elderly patients with hepatocellular carcinoma.	World J Gastroenterol	18	1926-1932	2012
Imakiire K, Uto H, Sato Y, Sasaki F, Mawatari S, Ido S, Shimoda K, Hayashi K, Stuver SO, Ito Y, <u>Okanoue T.</u> Tsubouchi H.	Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C.	Mol Med Report	6	259-264	2012
Karino Y, <u>Toyota J.</u> Ikeda K, Suzuki F, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Dennis Hernandez, Fei Yu, Fiona McPhee, Kumada H.	Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir	J Hepatol	2012. 11. 012	In press	2012
Suzuki Y, Ikeda K, Suzuki F, <u>Toyota J.</u> Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Wenhua Hu, Timothy Eley, Fiona McPhee, Eric Hughes, Kumada H.	Dual Oral Therapy with Daclatasvir and Asunaprevir for Patients with HCV Genotype 1b Infection and Limited Treatment Options	J Hepatol	2012. 09. 037	In press	2012
Hayashi N, Okanoue T, Tsubouchi H, <u>Toyota J.</u> Chayama K, Kumada H.	Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C	J Viral Hepat	19	134-142	2012
小関 至、狩野吉康、 <u>豊田成司</u> 、高橋祥一、川上由育、茶山一彰、芥田憲夫、鈴木文孝、熊田博光	PEG-IFN/Ribavirin/Telaprevir 三剤併用療法における薬剤投与率の抗ウイルス効果におよぼす影響	肝臓	53(2)	69-77	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Naiki T, Nakayama N, Mochida S, Oketani M, Takikawa Y, Suzuki K, Tada SI, Ichida T, <u>Moriwaki H</u> , Tsubouchi H; the Intractable Hepato-Biliary Disease Study Group supported by the Ministry of Health, Labor and Welfare of Japan.	Novel scoring system as a useful model to predict the outcome of patients with acute liver failure: Application to indication criteria for liver transplantation.	Hepatol Res	42	68-75	2012
Shimizu M, Shirakami Y, Sakai H, Iwasa J, Shiraki M, Takai K, Naiki T, <u>Moriwaki H</u> .	Combination of acyclic retinoid with branched-chain amino acids inhibits xenograft growth of human hepatoma cells in nude mice.	Hepatol Res	42	1241-1247	2012
Terakura D, Shimizu M, Iwasa J, Baba A, Kochi T, Ohno T, Kubota M, Shirakami Y, Shiraki M, Takai K, Tsurumi H, Tanaka T, <u>Moriwaki H</u> .	Preventive effects of branched-chain amino acid supplementation on the spontaneous development of hepatic preneoplastic lesions in C57BL/KsJ-db/db obese mice.	Carcinogenesis	33	2499-2506	2012
Shimizu M, Imai K, Takai K, <u>Moriwaki H</u> .	Role of acyclic retinoid in the chemoprevention of hepatocellular carcinoma: Basic aspects, clinical applications, and future prospects.	Curr Cancer Drug Targets	12	1119-1128	2012
Shimizu M, Shirakami Y, Imai K, Takai K, <u>Moriwaki H</u> .	Acyclic retinoid in chemoprevention of hepatocellular carcinoma: targeting phosphorylated retinoid X receptor- $\alpha$ for prevention of liver carcinogenesis.	J Carcinog	11	11	2012
Shimizu M, Kubota M, Tanaka T, <u>Moriwaki H</u> .	Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis.	Int J Mol Sci	13	579-595	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ohno T, Shirakami Y, Shimizu M, Kubota M, Sakai H, Yasuda Y, Kochi T, Tsurumi H, <u>Moriwaki H.</u>	Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptorligand.	Cancer Lett	323	215-222	2012
Suzuki K, Endo R, Kohgo Y, Ohtake T, Ueno Y, Kato A, Suzuki K, Shiraki R, <u>Moriwaki H</u> , Habu D, Saito M, Nishiguchi S, Katayama K, Sakaida I;for the Japanese Nutritional Study Group for Liver Cirrhosis 2008.	Guidelines on nutritional management in Japanese patientswith liver cirrhosis from the perspective of preventing hepatocellular carcinoma.	Hepatol Res	42	621-626	2012
Hosokawa T, Kurosaki M, Tsuchiya K, Matsuda S, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Nakata T, Nishimura T, Suzuki S, Ueda K, Nakanishi H, Itakura J, Takahashi Y, <u>Izumi N.</u>	Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy.	World J Gastroenterol	19	249-57	2013
<u>Izumi N</u> , Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyota J, Inao M, Tanaka E, Moriwaki H, Adachi H, katsuyama S, Kudo M, Takaguchi K, Hiasa Y, Cahyama K, Yatsushashi H, Oketani M, Kumada H.	Inhibition of hepatocellular carcinoma by PegIFN $\alpha$ -2a in patients with chronic hepatitis C : a nationwide multicenter cooperative study.	J gastroenterol		In press	2013
Oze T, Hiramatsu N, Mita E, Akuta N, Sakamoto N, Nagano H, Itoh Y, Kaneko S, <u>Izumi N</u> , Nomura H, Hayashi N, Takehara T.	A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patientswith chronic hepatitis C in Japan.	Hepatol Res	43	35-43	2013
Tamaki N, Kurosaki M, Tanaka K, Suzuki Y, Hoshioka Y, Kato T, Yasui Y, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Asahina Y, <u>Izumi N.</u>	Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C.	J Viral Hepat	20	72-6	2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ueda T, Tsuchiya K, Hashimoto S, Inoue T, Enomoto N, Inao M, Tanaka A, Kaito M, Imazeki F, Nishiguchi S, Mochida S, Yokosuka O, Yatsuhashi H, <u>Izumi N</u> , Kudo M.	Retreatment with peginterferon $\alpha$ -2a + ribavirin in patients who failed previous peginterferon $\alpha$ -2b + ribavirin combination therapy.	Dig Dis	30	554-60	2012
Toyoda H, Kumada T, Shimada N, Takaguchi K, Ide T, Sata M, Ginba H, Matsuyama K, <u>Izumi N</u> .	Significance of a reduction in HCVRNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin.	BMC Infect Dis	12	324	2012
Hasegawa K, Kokudo N, Makuuchi M, <u>Izumi N</u> , Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y.	Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey.	J Hepatol	In press		2013
Toyoda H, Kumada T, Shimada N, Takaguchi K, Ide T, Sata M, Ginba H, Matsuyama K, <u>Izumi N</u> .	Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.	J Med Virol	85	65-70	2013
Ikeda K, <u>Izumi N</u> , Tanaka E, Yotsuyanagi H, Takahashi Y, Fukushima J, Kondo F, Fukusato T, Koike K, Hayashi N, Kumada H.	Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis B.	Hepatol Res	In press		2013
Osaki Y, Ikeda K, <u>Izumi N</u> , Yamashita S, Kumada H, Hatta S, Okita K.	Clinical effectiveness of bipolar radiofrequency ablation for small liver cancer.	J Gastroenterol	In press		2013

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa A, Hidaka H, Iso Y, Kubota K, Shimada M, Utsunomiya T, Hirooka M, Hiasa Y, Toyoki Y, Hakamada K, Yasui K, Kumada T, Toyoda H, Sato S, Hisai H, Kuzuya T, Tsuchiya K, <u>Izumi N</u> , Arii S, Nishio K, Kudo M.	FGF3/FGF4 amplification and multiple lung metastasis in responders to sorafenib in hepatocellular carcinoma.	Hepatology	In press		2012
Kudo M, Tateishi R, Yamashita T, Ikeda M, Furuse J, Ikeda K, Kokudo N, <u>Izumi N</u> , Matsui O.	Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system.	Clin Drug Investig	32	37-51	2012
Akiba T, Hora K, Imawari M, Sato C, Tanaka E, <u>Izumi N</u> , Harada T, Ando R, Kikuchi K, Tomo T, Hirakata H, Akizawa T.	2011 Japanese society for dialysis therapy guidelines for the treatment of hepatitis C virus infection in dialysis patients.	Ther Apher Dial	16	289-310	2012
Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Matsuura K, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Tokunaga K, Mizokami M, <u>Izumi N</u> .	A model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.	J Med Virol	85	449-58	2013
Nishida N, Sawai H, Matsuura K, Sugiyama M, Ahn SH, Park JY, Hige S, Kang JH, Suzuki K, Kurosaki M, Asahina Y, Mochida S, Watanabe M, Tanaka E, Honda M, Kaneko S, Orito E, Itoh Y, Mita E, Tamori A, Murawaki Y, Hiasa Y, Sakaida I, Korenaga M, Hino K, Ide T, Kawashima M, Mawatari Y, Sageshima M, Ogasawara Y, Koike A, <u>Izumi N</u> , Han KH, Tanaka Y, Tokunaga K, Mizokami M.	Genome-wide association study confirming association of HLS-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean.	PLoS One	7	E39175	2012



発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Sawai H, Nishida N, Mbarek H, Matsuda K, Mawatari Y, Yamaoka M, Hige S, Kang JH, Abe K, Mochida S, Watanabe M, Kurosaki M, Asahina Y, <u>Izumi N</u> , Honda M, Kaneko S, Tanaka E, Matsuura K, Itoh Y, Mita E, Korenaga M, Hino K, Murawaki Y, Hiasa Y, Ide T, Ito K, Sugiyama M, Ahn SH, Han KH, Park JY, Yuen MF, Nakamura Y, Tanaka Y, Mizokami M, Tokunaga K.	No association for Chinese HBV-related hepatocellular Carcinoma susceptibility SNP in other East Asian populations.	BMC Med Genet	13	47	2012
Ito K, Kuno A, Ikehara Y, Sugiyama M, Saito H, Aoki Y, Matsui T, Imamura M, Korenaga M, Murata K, Masaki N, Tanaka Y, Hige S, <u>Izumi N</u> , Kurosaki M, Nishiguchi S, Sakamoto M, Kage M, Narimatsu H, Mizokami M.	Lec-Hepa, a glycol-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients.	Hepatology	56	1448-56	2012
Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, Tamaki N, Hoshioka Y, Yasui Y, Katoh T, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nitta S, Sakamoto N, <u>Izumi N</u> .	Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.	Hepatology	55	20-9	2012
Kurosaki M, Hiramatsu N, Sakamoto M, Iwasaki M, Tamori A, Matsuura K, Kakinuma S, Sugauchi F, Sakamoto N, Nakagawa M, <u>Izumi N</u> .	Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C.	J Hepatol	56	602-8	2012
Kurosaki M, Hiramatsu N, Sakamoto M, Suzuki Y, Iwasaki M, Tamori A, Matsuura K, Kakinuma S, Sugauchi F, Sakamoto N, Nakagawa M, Yatsugasgi H, <u>Izumi N</u> .	Age and ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis.	Antivir Ther	17	35-43	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Izumi N.</u>	Prediction and prevention of intrahepatic recurrence of hepatocellular carcinoma.	Hepatol Res	42	226-32	2012
Matsumoto A, <u>Tanaka E</u> , Suzuki Y, Kobayashi M, Tanaka Y, Shinkai N, Hige S, Yatsuhashi H, Nagaoka S, Chayama K, Tsuge M, Yokosuka O, Imazeki F, Nishiguchi S, Saito M, Fujiwara K, Torii N, Hiramatsu N, Karino Y, Kumada H.	Combination of hepatitis B viralantigens and DNA for Prediction of relapse after Discontinuation of nucleos(t)ide analogs in patients with chronichepatitis B.	Hepatol Res	42	139-149	2012
Matsumoto A, <u>Tanaka E</u> , Morita S, Yoshizawa K, Umemura T, Joshita S.	Changes in the serum level of hepatitis B virus (HBV) surfaceantigen over the natural course of HBV infection.	J Gastroenterol	47	1006-1013	2012
<u>Tanaka E</u> , Urata Y.	Risk of hepatitis B reactivation in patients treated with tumor necrosis factor-alpha inhibitors.	Hepatol Res	42	333-339	2012
Joshita S, Umemura T, Katsuyama Y, Ichikawa Y, Kimura T, Morita S, Kamijo A, Komatsu M, Ichijo T, Matsumoto A, Yoshizawa K, Kamijo N, Ota M, <u>Tanaka E</u> .	Association of IL28B gene polymorphism with developmentof hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection.	Hum Immunol	73	298-300	2012
Tanimoto Y, Tashiro H, Aikata H, Amano H, Oshita A, Kobayashi T, Kuroda S, Tazawa H, Takahashi S, Itamoto T, <u>Chayama K</u> , Ohdan H.	Impact of pegylated interferon therapy on outcomes of patientswith hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection.	Ann Surg Oncol.	19	418-425	2012
Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, <u>Chayama K</u> , Kawakami Y, Ishikawa H, Watanabe H. Hu W, Eley T, McPhee F, Hughes E, Kumada H.	Dual Oral Therapy with Daclatasvir and Asunaprevir for Patients with HCV Genotype 1b Infection and Limited TreatmentOptions.	J Hepatol.			2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Sainz B, Jr., Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, <u>Chayama K</u> , Alrefai WA, Uprichard SL.	Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor.	Nat Med.	18	281-285	2012
Ohnishi M, Tsuge M, Kohno T, Zhang Y, Abe H, Hyogo H, Kimura Y, Miki D, Hiraga N, Imamura M, Takahashi S, Ochi H, Hayes CN, Tanaka S, Arihiro K, <u>Chayama K</u> .	IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients.	J gastroenterol.	47	834-844	2012
Ochi H, Hayes CN, Abe H, Hayashida Y, Uchiyama T, Kamatani N, Nakamura Y, <u>Chayama K</u> .	Toward the establishment of a prediction system for the personalized treatment of chronic hepatitis C.	J Infect Dis.	205	204-210	2012
Nagaoki Y, Aikata H, Kobayashi T, Fukuhara T, Masaki K, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Tsuge M, Hiramatsu A, Imamura M, Hyogo H, Kawakami Y, Takahashi S, Ochi H, <u>Chayama K</u> .	Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis.	J gastroenterol.			2012
Murakami E, Aikata H, Miyaki D, Nagaoki Y, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Takahashi S, Kimura T, Kenjo M, Nagata Y, Ishikawa M, Kakizawa H, Awai K, <u>Chayama K</u> .	Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava.	Hepatol Res.	42	442-453	2012
Miki D, Ohishi W, Ochi H, Hayes CN, Abe H, Tsuge M, Imamura M, Kamatani N, Nakamura Y, <u>Chayama K</u> .	Serum PAI-1 is a novel predictor for response to pegylated interferon-alpha-2b plus ribavirin therapy in chronic hepatitis C virus infection.	J Viral Hepat.	19	e126-133	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Matsuo J, Mizui M, Okita H, Katayama K, Aimitsu S, Sakata T, Obayashi M, Nakanishi T, <u>Chayama K</u> , Miyakawa Y, Yoshizawa H, Tanaka J, for the Hiroshima Hepatitis Study G.	Follow up of the 987 blood donors found with hepatitis C virus infection over 9-18 years.	Hepatol Res.	42	637-647	2012
Kumada H, Toyota J, Okanoue T, <u>Chayama K</u> , Tsubouchi H, Hayashi N.	Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.	J Hepatol.	56	78-84	2012
Kobayashi M, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Hosaka T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Chayama K</u> , Miyakawa Y, Kumada H.	Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus.	J gastroenterol.	47	596-605	2012
Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Onoe T, Tashiro H, Ohdan H, <u>Chayama K</u> .	Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.	J Gastroenterol Hepatol.	27	1467-1472	2012
Karino Y, Toyota J, Ikeda K, Suzuki F, <u>Chayama K</u> , Kawakami Y, Ishikawa H, Watanabe H, Hernandez D, Yu F, McPhee F, Kumada H.	Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.	J Hepatol.			2012
Tanimoto Y, Tashiro H, Aikata H, Amano H, Oshita A, Kobayashi T, Kuroda S, Tazawa H, Takahashi S, Itamoto T, <u>Chayama K</u> , Ohdan H.	Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection.	Ann Surg Oncol.	19	418-425	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hayes CN, Imamura M, Aikata H, <u>Chayama K.</u>	Genetics of IL28B and HCV – response to infection and treatment.	Gastroenterology &Hepatology	9	406-417	2012
Hayashi N, Okanoué T, Tsubouchi H, Toyota J, <u>Chayama K.</u> , Kumada H.	Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C.	Journal of Viral Hepatitis	19	134-142	2012
<u>Chayama K.</u> , Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H.	Dual Therapy With the Nonstructural Protein 5A Inhibitor, Daclatasvir, and the Nonstructural Protein 3 Protease Inhibitor, Asunaprevir, in Hepatitis C Virus Genotype 1b-Infected Null Responders.	Hepatology	55	742-748	2012
<u>Chayama K.</u> , Hayes CN, Ohishi W, Kawakami Y.	Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines.	J Gastroenterol	48	1-12	2013
<u>Chayama K.</u> , Hayes CN, Imamura M.	Impact of interleukin-28B genotype on in vitro and in vivo systems of hepatitis C virus replication.	Hepatology Research	42	841-853	2012
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Chayama K.</u> , Nakamura Y, Kumada H.	Amino Acid substitution in HCV Core/NS5A Region and Genetic Variation Near IL28B Gene Affect Treatment Efficacy to Interferon plus Ribavirin Combination Therapy.	Intervirolgy	55	231-241	2012
Yanagimoto S, Yotsuyanagi H, Kikuchi Y, Tsukada K, Kato M, Takamatsu J, Hige S, <u>Chayama K.</u> , Moriya K, Koike K.	Chronic hepatitis B in patients coinfecting with human immunodeficiency virus in Japan: a retrospective multicenter analysis.	J Infect Chemother	18	883-890	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Okazaki A, Hiraga N, Imamura M, Hayes CN, Tsuge M, Takahashi S, Aikata H, Abe H, Miki D, Ochi H, Tateno C, Yoshizato K, Ohdan H, <u>Chayama K.</u>	Severe Necroinflammatory Reaction Caused by Natural Killer Cell-Mediated Fas/Fas Ligand Interaction and Dendritic Cells in Human Hepatocyte Chimeric Mouse.	Hepatology	56	555-566	2012
Ohishi W, <u>Chayama K.</u>	Treatment of chronic hepatitis B with nucleos(t)ide analogues.	Hepatology Research	42	219-225	2012
Nagaoki Y, Hyogo H, Aikata H, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, <u>Chayama K.</u>	Recent trend of clinical features in patients with hepatocellular carcinoma.	Hepatol Res.	42	368-375	2012
Miki D, Ochi H, Hayes CN, Aikata H, <u>Chayama K.</u>	Hepatocellular carcinoma: towards personalized medicine.	Cancer Sci.	103	846-850	2012
Matsumoto A, Tanaka E, Suzuki Y, Kobayashi M, Tanaka Y, Shinkai N, Hige S, Yatsushashi H, Nagaoka S, <u>Chayama K.</u> Tsuge M, Yokosuka O, Imazeki F, Nishiguchi S, Saito M, Fujiwara K, Torii N, Hiramatsu N, Karino Y, Kumada H.	Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B.	Hepatol Res.	42	139-149	2012
Hayes CN, Akamatsu S, Tsuge M, Miki D, Akiyama R, Abe H, Ochi H, Hiraga N, Imamura M, Takahashi S, Aikata H, Kawaoka T, Kawakami Y, Ohishi W, <u>Chayama K.</u>	Hepatitis B Virus-Specific miRNAs and Argonaute2 Play a Role in the Viral Life Cycle.	PLoS One.	7	e47490	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, Arai Y, Takahashi H, Shirakihara T, Nagasaki M, Shibuya T, Nakano K, Watanabe-Makino K, Tanaka H, Nakamura H, Kusuda J, Ojima H, Shimada K, Okusaka T, Ueno M, Shigekawa Y, Kawakami Y, Arihiro K, Ohdan H, Gotoh K, Ishikawa O, Ariizumi S, Yamamoto M, Yamada T, <u>Chayama K</u> , Kosuge T, Yamaue H, Kamatani N, Miyano S, Nakagama H, Nakamura Y, Tsunoda T, Shibata T, Nakagawa H.	Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators.	Nat Genet.	44	760-764	2012
Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi H, Katsushima S, Kudo M, Takaguchi K, Hiasa Y, <u>Chayama K</u> , Yatsuhashi H, Oketani M, Kumada H.	Inhibition of hepatocellular carcinoma by PegIFNalpha-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study.	J gastroenterol.			2012
Yokoyama K, Anan A, Iwata K, Nishizawa S, Morihara D, Ueda S, Sakurai K, Iwashita H, Hirano G, Sakamoto M, Takeyama Y, Irie M, Shakado S, Sohda T, <u>Sakisaka S</u> .	Limitation of Repeated Radiofrequency Ablation in Hepatocellular Carcinoma: Proposal of a 3 (times)-3 (years)-INDEX.	J Gastroenterol Hepatol	27(6)	1044-1050	2012
Hirano G, Sakurai K, Sohda T, Kunimoto H, Yotsumoto K, Fukunaga A, Iwashita H, Ueda S, Yokoyama K, Morihara D, Takeyama Y, Sakamoto M, Irie M, Iwata K, Shakado S, <u>Sakisaka S</u> .	Systemic Chemotherapy Using Carboplatin and 5-Fluorouracil for Extrahepatic Metastasis of Hepatocellular Carcinoma.	Hepatogastroenterology	59(2)		2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Morihara D, Iwata K, Hanano T, Kunimoto H, Kuno S, Fukunaga A, Yotsumoto K, Takata K, Tanaka T, Sakurai K, Iwashita H, Ueda S, Hirano G, Yokoyama K, Nakane H, Nishizawa S, Yoshikane M, Anan A, Takeyama Y, Kakumitsu S, Kitamura Y, Sakamoto M, Irie M, Shakado S, Sohda T, Watanabe H, <u>Sakisaka S.</u>	Late-evening snack with branched-chain amino acids improves liver function after radiofrequency ablation for hepatocellular carcinoma.	Hepatology Research	42	658-667	2012
Tanaka T, Shakado S, Takata K, Inomata S, Ueda S, Morihara D, Yokoyama K, Nishizawa S, Sakamoto M, Anan A, Takeyama Y, Irie M, Iwata K, Sohda T, <u>Sakisaka S.</u>	Hepatitis C virus-infected patients with persistently normal alanine aminotransferase levels whose platelet count less than 150,000/ $\mu$ L and whose age over 55 years old should be recommended antiviral therapy.	Med. Bull. Fukuoka Univ	39(2)	103-112	2012
Hikita H, Kodama T, Shimizu S, Li W, Shigekawa M, Tanaka S, Hosui A, Miyagi T, Tatsumi T, Kanto T, Hiramatsu N, Morii E, Hayashi N, <u>Takehara T.</u>	Bak deficiency inhibits liver carcinogenesis: A causal link between apoptosis and carcinogenesis.	J Hepatol.	57(1)	92-100.	2012
Oze T, Hiramatsu N, Song C, Yakushijin T, Iio S, Doi Y, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Hayashi N, <u>Takehara T.</u>	Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin.	J Gastroenterol.	47(3)	334-42	2012
Imakiire K, Uto H, Sato Y, Sasaki F, Mawatari S, <u>Ido A.</u> Shimoda K, Hayashi K, Stuver SO, Ito Y, Okanoue T, Tsubouchi H	Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C.	Mol Med Rep	6	259-264	2012



発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tsubouchi N, Uto H, Kumagai K, Sasaki F, Kanmura S, Numata M, Moriuchi A, Oketani M, <u>Ido A</u> , Hayashi K, Kusumoto K, Shimoda K, Stuver SO, Tsubouchi H	Impact of antibody to hepatitis B core antigen on the clinical course of hepatitis C virus carriers in a hyperendemic area in Japan: A community-based cohort study.	Hepatol Res. 2013 Feb 18.		doi: 10.1111/he pr.12075. [Epub ahead of print]	2013
Ozaki T, Yamazaki K, Iwasaki T, Okano T, Kurosaki Y, Nakamura K, Fujioka T, <u>Yotsuyanagi H</u>	$\alpha$ 2-HS glycoprotein is an essential component of cryoglobulin associated with chronic hepatitis C.	Clin Chem Lab Med.			2012
Takeji S, Hirooka M, Koizumi Y, Tokumoto Y, Abe M, Ikeda Y, Nadano S, <u>Hiasa Y</u> , Onji M.	Des-gamma-carboxy prothrombin identified by P-11 and P-16 antibodies reflects prognosis for patients with hepatocellular carcinoma.	J Gastroenterol Hepatol.	E-pub		2012
Uesugi K, <u>Hiasa Y</u> , Tokumoto Y, Mashiba T, Koizumi Y, Hirooka M, Abe M, Matsuura B, Onji M.	Wilms' tumor 1 gene modulates Fas-related death signals and anti-apoptotic functions in hepatocellular carcinoma.	J Gastroenterol.	E-pub		2012
Miyake T, <u>Hiasa Y</u> , Hirooka M, Tokumoto Y, Watanabe T, Furukawa S, Ueda T, Yamamoto S, Kumagi T, Miyaoka H, Abe M, Matsuura B, Onji M.	High serum palmitic acid is associated with low antiviral effects of interferon-based therapy for hepatitis C virus.	Lipids	47	1601-9	2012
Tada F, Abe M, Hirooka M, Ikeda Y, <u>Hiasa Y</u> , Lee Y, Jung NC, Lee WB, Lee HS, Bae YS, Onji M.	Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.	Int J Oncol	41	1601-9	2012
Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa A, Hidaka H, Iso Y, Kubota K, Shimada M, Utsunomiya T, Hirooka M, <u>Hiasa Y</u> , Toyoki Y, Hakamada K, Yasui K, Kumada T, Toyoda H, Sato S, Hisai H, Kuzuya T, Tsuchiya K, Izumi N, Arii S, Nishio K, Kudo M.	FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.	Hepatology	E-pub		2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Akbar SM, Chen S, Al-Mahtab M, Abe M, <u>Hiasa Y.</u> Onji M.	Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.	Antiviral Res	96	59-64	2012
Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi H, Katsushima S, Kudo M, Takaguchi K, <u>Hiasa Y.</u> Chayama K, Yatsunami H, Oketani M, Kumada H.	Inhibition of hepatocellular carcinoma by PegIFN $\alpha$ -2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study.	J Gastroenterol	E-pub		2012
Nishida N, Sawai H, Matsuura K, Sugiyama M, Ahn SH, Park JY, Hige S, Kang JH, Suzuki K, Kurosaki M, Asahina Y, Mochida S, Watanabe M, Tanaka E, Honda M, Kaneko S, Orito E, Itoh Y, Mita E, Tamori A, Murawaki Y, <u>Hiasa Y.</u> , Sakaida I, Korenaga M, Hino K, Ide T, Kawashima M, Mawatari Y, Sageshima M, Ogasawara Y, Koike A, Izumi N, Han KH, Tanaka Y, Tokunaga K, Mizokami M.	Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean.	PLoS One	7	e39175	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Sawai H, Nishida N, Mbarek H, Matsuda K, Mawatari Y, Yamaoka M, Hige S, Kang JH, Abe K, Mochida S, Watanabe M, Kurosaki M, Asahina Y, Izumi N, Honda M, Kaneko S, Tanaka E, Matsuura K, Itoh Y, Mita E, Korenaga M, Hino K, Murawaki Y, <u>Hiasa Y</u> , Ide T, Ito K, Sugiyama M, Ahn SH, Han KH, Park JY, Yuen MF, Nakamura Y, Tanaka Y, Mizokami M, Tokunaga K.	No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations.	BMC Med Genet	13	47	2012
Yamamoto Y, <u>Hiasa Y</u> , Murakami H, Ikeda Y, Yamanishi H, Abe M, Matsuura B, Onji M.	Rapid alternative absorption of dietary long-chain fatty acids with upregulation of intestinal glycosylated CD36 in liver cirrhosis.	Am J Clin Nutr	96	90-101	2012
Ochi H, Hirooka M, Koizumi Y, Miyake T, Tokumoto Y, Soga Y, Tada F, Abe M, <u>Hiasa Y</u> , Onji M.	Real-time tissue elastography forevaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases.	Hepatology	56	1271-8	2012
Tokumoto Y, <u>Hiasa Y</u> , Uesugi K, Watanabe T, Mashiba T, Abe M, Kumagi T, Ikeda Y, Matsuura B, Onji M.	Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8.	J Infect Dis	205	1121-30	2012
Miyake T, Kumagi T, Hirooka M, Koizumi M, Furukawa S, Ueda T, Tokumoto Y, Ikeda Y, Abe M, Kitai K, <u>Hiasa Y</u> , Matsuura B, Onji M.	Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study.	J Gastroenterol	47	696-703	2012
Kumagi T, Drenth JP, Guttman O, Ng V, Lilly L, Theraponos G, <u>Hiasa Y</u> , Michitaka K, Onji M, Watanabe Y, Sen S, Griffiths W, Roberts E, Heathcote J, Hirschfield GM.	Biliary atresia and survival into adulthood without transplantation: a collaborative multicentre clinic review.	Liver Int	32	510-8	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ogawa E, Furusyo N, Kajiwara E, Takahashi K, <u>Nomura H</u> , Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J.	Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: A prospective, multicenter study J.	J Hepatol	(in press)		
Miyagi Y, <u>Nomura H</u> , Yamashita N, Tanimoto H, Ito K, Masaki N, Mizokami M, Shibuya T.	Estimation of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA during PEG-IFN plus ribavirin therapy by HCV genotypes and IL28B genotype.	J Infect Chemother	(in press)		
Ogawa E, Furusyo N, Kajiwara E, Takahashi K, <u>Nomura H</u> , Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J.	An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.	J Infect Chemother	18	689-697	2012
Saito H, Ito K, Sugiyama M, Matsui T, Aoki Y, Imamura M, Murata K, Masaki N, <u>Nomura H</u> , Adachi H, Hige S, Enomoto N, Sakamoto N, Kurosaki M, Mizokami M, Watanabe S.	Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients.	Hepatol Res.	42	958-965	2012
Ogawa E, Furusyo N, Kajiwara E, Takahashi K, <u>Nomura H</u> , Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J.	An evaluation of the adverse effect of premature discontinuation of pegylated interferon alpha-2b and ribavirin treatment for chronic hepatitis C virus infection: Results from Kyushu University Liver Disease Study (KULDS).	J Gastroenterol Hepatol.	27	1233-1240	2012
Kainuma M, Furusyo N, Azuma K, Kajiwara E, Takahashi K, <u>Nomura H</u> , Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Shimoda S, Hayashi J.	Pegylated interferon $\alpha$ -2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase.	Hepatol Res.	42	33-41	2012